Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now
https://www.zacks.com/stock/news/2210387/here-is-why-growth-investors-should-buy-novo-nordisk-nvo-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2210387
Jan 15, 2024 - Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
0
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
https://www.zacks.com/stock/news/2213007/adc-therapeutics-adct-rises-43-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213007
Jan 19, 2024 - ADC Therapeutics (ADCT) surges after it provides business updates that highlight the company's progress with its pipeline. Multiple data readouts are expected throughout this year.
0
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
https://www.zacks.com/stock/news/2213681/will-the-individual-ma-unit-aid-humana-s-hum-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213681
Jan 22, 2024 - Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
0
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2213778/novo-nordisk-nvo-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2213778
Jan 22, 2024 - Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
Top Stock Reports for Apple, Visa & Novo Nordisk
https://www.zacks.com/commentary/2217814/top-stock-reports-for-apple-visa-novo-nordisk?cid=CS-ZC-FT-research_daily-2217814
Jan 30, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Visa Inc. (V) and Novo Nordisk A/S (NVO).
0
ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4
https://www.zacks.com/stock/news/2218851/adp-cools-to-107k-private-sector-jobs-ba-nvo-beat-in-q4?cid=CS-ZC-FT-ahead_of_wall_street-2218851
Jan 31, 2024 - We've now spent a full six months sub-200K private-sector job gains per month.
0
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
https://www.zacks.com/stock/news/2220495/3-reasons-growth-investors-will-love-novo-nordisk-nvo?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_11_growth-2220495
Feb 02, 2024 - Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0